TY  - JOUR
AU  - Wiese, M.
AU  - Schill, F.
AU  - Sturm, D.
AU  - Pfister, S.
AU  - Hulleman, E.
AU  - Johnsen, S. A.
AU  - Kramm, C. M.
TI  - No Significant Cytotoxic Effect of the EZH2 Inhibitor Tazemetostat (EPZ-6438) on Pediatric Glioma Cells with Wildtype Histone 3 or Mutated Histone 3.3.
JO  - Klinische Pädiatrie
VL  - 228
IS  - 3
SN  - 1439-3824
CY  - Stuttgart
PB  - Thieme
M1  - DKFZ-2017-06011
SP  - 113 - 117
PY  - 2016
AB  - Glioblastoma multiforme (GBM) and diffuse intrinsic pontine glioma (DIPG) belong to the most aggressive cancers in children with poor prognosis and limited therapeutic options. Therapeutic targeting of epigenetic proteins may offer new treatment options. Preclinical studies identified Enhancer of Zeste Homolog 2 (EZH2) within polycomb repressor complex 2 (PRC2) as a potential epigenetic anti-tumor target in adult GBM cells but similar inhibition studies in pediatric GBM/DIPG were still missing. Moreover, approximately 30
KW  - Benzamides (NLM Chemicals)
KW  - EPZ-6438 (NLM Chemicals)
KW  - Histones (NLM Chemicals)
KW  - Pyridones (NLM Chemicals)
KW  - EZH2 protein, human (NLM Chemicals)
KW  - Enhancer of Zeste Homolog 2 Protein (NLM Chemicals)
LB  - PUB:(DE-HGF)16
C6  - pmid:27135271
DO  - DOI:10.1055/s-0042-105292
UR  - https://inrepo02.dkfz.de/record/130935
ER  -